AU2006214325B2 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells - Google Patents

Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells Download PDF

Info

Publication number
AU2006214325B2
AU2006214325B2 AU2006214325A AU2006214325A AU2006214325B2 AU 2006214325 B2 AU2006214325 B2 AU 2006214325B2 AU 2006214325 A AU2006214325 A AU 2006214325A AU 2006214325 A AU2006214325 A AU 2006214325A AU 2006214325 B2 AU2006214325 B2 AU 2006214325B2
Authority
AU
Australia
Prior art keywords
cells
skin
antagonist
cla
cutaneous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006214325A
Other languages
English (en)
Other versions
AU2006214325A1 (en
Inventor
Janine Bilsborough
Jane A. Gross
Donald Y. M. Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
National Jewish Health
Original Assignee
Zymogenetics Inc
National Jewish Medical and Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, National Jewish Medical and Research Center filed Critical Zymogenetics Inc
Publication of AU2006214325A1 publication Critical patent/AU2006214325A1/en
Application granted granted Critical
Publication of AU2006214325B2 publication Critical patent/AU2006214325B2/en
Priority to AU2012202218A priority Critical patent/AU2012202218B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
AU2006214325A 2005-02-14 2006-02-14 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells Ceased AU2006214325B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202218A AU2012202218B2 (en) 2005-02-14 2012-04-17 Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US65311405P 2005-02-14 2005-02-14
US60/653,114 2005-02-14
US71676205P 2005-09-13 2005-09-13
US60/716,762 2005-09-13
US74995205P 2005-12-13 2005-12-13
US60/749,952 2005-12-13
PCT/US2006/005327 WO2006088955A2 (en) 2005-02-14 2006-02-14 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202218A Division AU2012202218B2 (en) 2005-02-14 2012-04-17 Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells

Publications (2)

Publication Number Publication Date
AU2006214325A1 AU2006214325A1 (en) 2006-08-24
AU2006214325B2 true AU2006214325B2 (en) 2012-04-05

Family

ID=36685803

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006214325A Ceased AU2006214325B2 (en) 2005-02-14 2006-02-14 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
AU2006214326A Ceased AU2006214326B2 (en) 2005-02-14 2006-02-14 Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006214326A Ceased AU2006214326B2 (en) 2005-02-14 2006-02-14 Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists

Country Status (8)

Country Link
US (11) US20060188500A1 (https=)
EP (2) EP1856150A2 (https=)
JP (2) JP4927762B2 (https=)
AU (2) AU2006214325B2 (https=)
CA (2) CA2595939C (https=)
IL (3) IL184734A (https=)
MX (2) MX2007009471A (https=)
WO (2) WO2006088956A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
WO2001023556A1 (en) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
CA2594502A1 (en) * 2005-01-28 2006-08-03 Zymogenetics Inc. Homogeneous preparations of il-31
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US20060188500A1 (en) 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
DK2594586T3 (en) * 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US10060273B2 (en) 2015-04-15 2018-08-28 United Technologies Corporation System and method for manufacture of abrasive coating
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
IL326629A (en) * 2018-04-25 2026-04-01 Kiniksa Pharmaceuticals Ltd Treatment of skin diseases or disorders through administration of anti-OSMR BETA antibody
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
RU2707181C1 (ru) * 2019-08-15 2019-11-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови
CN114728064B (zh) 2019-11-20 2025-05-06 中外制药株式会社 含抗体制剂
KR102392954B1 (ko) * 2020-02-11 2022-05-02 연세대학교 산학협력단 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060090A2 (en) * 2002-01-18 2003-07-24 Zymogenetics, Inc. Novel cytokine zcytor17 ligand
US20030215838A1 (en) * 2002-01-18 2003-11-20 Sprecher Cindy A. Cytokine receptor zcytor17 multimers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US20040235955A1 (en) 2001-09-14 2004-11-25 Masami Narita Remedies for pruritus
JP2004219390A (ja) * 2002-02-22 2004-08-05 Taisho Pharmaceut Co Ltd アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法
JPWO2003070252A1 (ja) 2002-02-22 2005-06-09 大正製薬株式会社 止痒剤
JP2004107209A (ja) * 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
JP4503942B2 (ja) * 2003-06-11 2010-07-14 大正製薬株式会社 止痒剤
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
CA2594502A1 (en) 2005-01-28 2006-08-03 Zymogenetics Inc. Homogeneous preparations of il-31
JP2008530132A (ja) * 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US20060188500A1 (en) 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
CN102321174B (zh) * 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
WO2007037137A1 (ja) * 2005-09-28 2007-04-05 Konica Minolta Opto, Inc. 射出成形装置
WO2007133816A2 (en) * 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
EP2796466B1 (en) * 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060090A2 (en) * 2002-01-18 2003-07-24 Zymogenetics, Inc. Novel cytokine zcytor17 ligand
US20030215838A1 (en) * 2002-01-18 2003-11-20 Sprecher Cindy A. Cytokine receptor zcytor17 multimers
US20030224487A1 (en) * 2002-01-18 2003-12-04 Sprecher Cindy A. Novel cytokine zcytor17 ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dillon, S. R. et al (2004) Nature Immunology 5(7): 752-760 *

Also Published As

Publication number Publication date
IL184776A (en) 2014-06-30
EP1856539A2 (en) 2007-11-21
US20090092999A1 (en) 2009-04-09
US20090280121A1 (en) 2009-11-12
US20190040125A1 (en) 2019-02-07
US8388964B2 (en) 2013-03-05
EP1856539B1 (en) 2015-10-21
US20130203070A1 (en) 2013-08-08
JP2008530137A (ja) 2008-08-07
IL184776A0 (en) 2007-12-03
US20170096484A1 (en) 2017-04-06
WO2006088955A2 (en) 2006-08-24
US20060188499A1 (en) 2006-08-24
AU2006214325A1 (en) 2006-08-24
US7723048B2 (en) 2010-05-25
IL219145A0 (en) 2012-06-28
CA2595939A1 (en) 2006-08-24
US20060188500A1 (en) 2006-08-24
US20100266600A1 (en) 2010-10-21
WO2006088955A3 (en) 2006-11-16
IL184734A0 (en) 2007-12-03
MX2007009471A (es) 2008-02-15
WO2006088956A3 (en) 2007-01-18
AU2006214326B2 (en) 2011-09-29
CA2595877A1 (en) 2006-08-24
JP2008530138A (ja) 2008-08-07
JP4927762B2 (ja) 2012-05-09
AU2006214326A1 (en) 2006-08-24
US20110212093A1 (en) 2011-09-01
MX2007009577A (es) 2008-01-30
US20130177563A1 (en) 2013-07-11
IL184734A (en) 2012-04-30
US8926957B2 (en) 2015-01-06
US8435745B2 (en) 2013-05-07
EP1856150A2 (en) 2007-11-21
CA2595939C (en) 2014-08-19
WO2006088956A2 (en) 2006-08-24
US20160024201A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
US11312779B2 (en) Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions
US8926957B2 (en) Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
AU2012202218B2 (en) Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE COINVENTOR NAME FROM BILLSBOROUGH, JANINE TO BILSBOROUGH, JANINE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired